Arcutis Biotherapeutics ARQT 深 滬
等待開盤 03-26 09:30:00 美东时间
22.74
+0.910
+4.17%
華盛通- 最 高23.00
- 今 開22.03
- 成交量 82.12万股
- 最 低 21.945
- 昨 收 21.83
- 總市值 28.21亿
- 52周最高 31.77
- 市盈率 靜 --
- 換手率 0.66%
- 52周最低 11.86
- 委 比 -83.95%
- 總股本 1.24亿
- 歷史最高 40.88
- 量 比 0.43
- 振 幅 4.83%
- 歷史最低 1.76
- 每 手 1
- 風險率 5.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Arcutis Biotherapeutics To Present New Data From Its Clinical Development Program And Marketed ZORYVE Portfolio
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new data from its
03-18 20:06
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
Arcutis Biotherapeutics will present new data on ZORYVE at the 2026 American Academy of Dermatology Annual Meeting. The presentations include late-breaking results from the INTEGUMENT-INFANT Phase 2 trial for infants with atopic dermatitis, as well as outcomes from the INTEGUMENT-OLE Phase 3 trial in children aged 2-5 years. Additional e-posters will highlight long-term results in seborrheic dermatitis and plaque psoriasis. ZORYVE (roflumilast), ...
03-18 12:00
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline
Arcutis Biotherapeutics Inc ($ARQT) announced an update on their ongoing clinic...
03-10 00:30
Arcutis Promotes Mas Matsuda to EVP and Chief Legal Officer
Arcutis Promotes Mas Matsuda to EVP and Chief Legal Officer Arcutis Biotherapeutics Inc. promoted Mas Matsuda from senior vice president and general counsel to executive vice president, chief legal officer, and corporate secretary. Matsuda, who joined the company in January 2022, will continue to le
03-05 22:03
BRIEF-Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
BRIEF-Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis March 3 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O : ARCUTIS BEGINS ENROLLING PHASE 1A/1B STUDY EVALUATING ARQ-234, A CD200R AGONIST, IN HEALTHY VOLUNTEE
03-03 21:03
Arcutis enrolls first participant in Phase 1a/1b ARQ-234 atopic dermatitis trial
Arcutis enrolls first participant in Phase 1a/1b ARQ-234 atopic dermatitis trial Arcutis Biotherapeutics Inc. announced enrollment of the first participant in ARQ-234-131, a Phase 1a/1b double-blind, randomized, placebo-controlled, first-in-human study evaluating the safety and tolerability of ARQ-2
03-03 21:03
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
电话会总结 ｜ Arcutis(ARQT)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Arcutis业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **第四季度业绩：** - 净产品收入：1.275亿美元，同比增长84%，环比增长29% - 净利润：1,740万美元，去年同期为净亏损1,080万美元 - 其他收入：200万美元（来自Wadog里程碑付款） - 销售成本：1,170万美元，去年同期为690万美元 - 研发费用：2,050万美元，去年同期为1,450万美元 - 销售及管理费用：7,900万美元，去年同期为5,760万美元 - 经营现金流：2,620万美元（正值） **全年业绩：** - 净产品收入：3.72
02-26 12:04
